Delivery Order SPE2DB20D3505-SPE2DB25FYCBJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,056.97 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml formulation) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, non-set-aside contract performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $97,446.44 on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen (2 ml units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FYCBJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,417.87 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen (2 ml) on August 29, 2025, with an ultimate completion date of September 2, 2025. This is a firm fixed price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, regularly supplies brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to federal medical procurement needs. This specific delivery order for Dupixent—a biologic medication used to treat conditions such as eczema, asthma, and chronic rhinosinusitis—represents one of numerous competitively awarded transactions the company fulfills through its DLA contract vehicle. The non-set-aside award demonstrates AmerisourceBergen's capability to meet federal procurement requirements in open competition and supports the Defense Health Agency and other government healthcare systems' pharmaceutical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 8/29/25 |